Phloroglucinol derivative capable of inhibiting PTP1B activity, and preparation method and applications thereof

Abstract

The invention discloses a phloroglucinol derivative capable of inhibiting PTP1B activity, and a preparation method and applications thereof, and more specifically relates to a phloroglucinol compound which is obtained via extraction and separation from Eugenia jambolana Lam seeds, a preparation method thereof, and applications of the phloroglucinol compound in preparing drugs used for treating diabetes and obesity, or inhibitors of protein tyrosine phosphatase 1B (PTP1B). The general molecular formula of the phloroglucinol compound is represented by formula I, wherein R1 is used for representing methyl or hydrogen, R2 is used for representing methyl or hydrogen, R1 and R2 are used for representing the same or the different groups, and R3 is used for representing an alkane or olefin side chain containing 12 to 26 carbon atoms. The phloroglucinol compound is a novel compound with excellent PTP1B inhibition effect; the PTP1B inhibition activity IC50 value ranges from 0.42 to 3.16<mu>M; the phloroglucinol compound can be used for preparing PTP1B inhibitors, and drugs used for treating diabetes, obesity, and complications of diabetes and obesity.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

AI Technical Summary

Benefits of technology

The technical effect of this patented method described by researchers has been explored through experiments conducted over different types of lipophilic substances called Phlorogenins A (PPT1) and B (Phlorigenin). These chemicals were found effective against various enzyme proteases involved in blood sugar metabolism such as p-glutathione peroxidase-1 , α -amyltransferase-2, transaminases, carboxypeptide hydrolase-3, amylopexymethyl transferring factor-4, cyclooxygenase 1, catalysed reactions involving other molecules like prostaglandine synthetase, gluconeotensors, adenosynthesis factors, histone deacetylating agents, etc., which are associated with abnormalities including type 2 diarrhea caused by insulitis, hyperlipemia, liver disease, necrosis, heart failure, stroke, arteriosclerotic diseases, cancer, Parkinson' s syndrome, Alzheimer’s Disease, autistic disorders, multiple sidedness, muscle spasms, dystonia, anxiety, sleep apnea, menstrual irregularities, gastrointestinal bleeding, hypopituitaria, sexual problems due to excessive weight loss, bariatric surgery, chronic renal impairment, cardiovascular conditions, strokes, brain damage from high levels of free radical oxygen species, inflammations, autoimmune responses, gene silencing, aging processes, tumor growth, painful joint movement, rheumatoid arthritis, skin burnings, eye injuries, wounds, ulcers, asthma attacks, immunological defenses, tissue regenerative medicine treatments, and drug development efforts aimed at finding new therapies targeting these mechanisms without causing negative side effects.

Problems solved by technology

This patented technical problem addressed in this patents relates to finding novel substances able to prevent excessive activation of certain enzyme proteins called pltype II/type 2 diabtesmimetics like Insulin Phenyl Sulfotransferases-1(PST1) and Stabilizers against glucose intake into cells due to their ability to lower glycaemia without causing harmful symptoms associated therewith.

Images